Skip to content
Screener

Aclaris Therapeutics ACRS Contingent consideration fair value adjustment

Contingent consideration fair value adjustment at other companies

Insmed logo
InsmedINSM
-$46.96M-357%
Blackrock logo
BlackrockBLK
$180M+2,100%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$622K—
Lifetime Brands logo
Lifetime BrandsLCUT
$0—
Lifetime Brands logo
Lifetime BrandsLCUT
$0—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$0—

Segments

By segment

See full
Single Reportable$300K—

Other financials

Income statement

See full
Revenue$1.6M-8.3%
Gross profit$1.4M+11.8%
Operating income-$24.2M-31.7%
Net income-$21.5M-39.4%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$19.2M-24.5%
Total debt$1.9M-21.8%
Total equity$124.6M-5.4%
Total assets$179.7M-5.0%

Cash flow

See full
Operating cash flow-$19.8M-98.6%
CapEx$58.0K+176%
Free cash flow-$19.9M-98.8%

Valuation

See full
Market cap$868.56M+389%
Enterprise value$851.24M+451%
P/S105.7×+95.1×

Profitability

See full
Gross margin79.5%-6.3pp
Operating margin-1,050.2%+266pp
Net margin-921.5%+161pp
FCF margin-756.5%—

Returns & leverage

See full
Return on equity-59.1%-17.4pp
Debt / equity0×0.0×
Current ratio3.5×-0.4×